[Polymyalgia rheumatica: What is the current status?]

Area of Science:

• Rheumatology
• Clinical Immunology
• Diagnostic Medicine

Context:

• Polymyalgia rheumatica (PMR) diagnosis relies on clinical signs and inflammatory markers, which are often unspecific.
• Differentiating PMR from other conditions presents a diagnostic challenge for healthcare professionals.
• Existing diagnostic methods necessitate improvement for accurate and timely patient management.

Purpose:

• To evaluate the diagnostic performance of the 2012 European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) consensus classification criteria for PMR.
• To assess the sensitivity and specificity of the new criteria in distinguishing PMR from other rheumatic diseases.
• To provide updated guidance for clinicians in the accurate diagnosis of polymyalgia rheumatica.

Summary:

• The 2012 EULAR/ACR consensus criteria for polymyalgia rheumatica demonstrate high diagnostic accuracy with 92.6% sensitivity and 91.2% specificity.
• These criteria aid in overcoming the diagnostic challenges posed by the unspecific nature of clinical symptoms and inflammatory markers in PMR.
• Current treatment standards involve glucocorticoids, with methotrexate and anti-interleukin-6 therapies as potential alternatives.

Impact:

• Improved diagnostic accuracy for polymyalgia rheumatica, leading to more appropriate patient stratification.
• Facilitation of earlier and more precise treatment initiation for patients with PMR.
• Potential for guiding future therapeutic strategies, including targeted biologic agents like anti-IL-6 therapies.